Synmosa Biopharma Capital Reinvestment Ratio
Synmosa Biopharma capital reinvestment ratio. Synmosa Biopharma (4114) has a Capital Reinvestment Ratio of 0.32x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$185.72 Million) in capital expenditures (NT$59.46 Million). Check Synmosa Biopharma (4114) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Synmosa Biopharma (2015–2025)
Capital reinvestment ratio of Synmosa Biopharma from 2015 to 2025. This chart tracks Synmosa Biopharma's Capital Reinvestment Ratio across 9 annual periods. Also explore Synmosa Biopharma net asset momentum to track the company's year-over-year net asset growth rate.
Synmosa Biopharma Capital Reinvestment Ratio by Year (2015–2025)
Synmosa Biopharma capital reinvestment ratio by year from 2015 to 2025. For the full cash flow conversion analysis, see how efficiently does Synmosa Biopharma generate cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.68x | NT$411.57 Million | NT$281.13 Million | ▲ +97.7% |
| 2024 | 0.35x | NT$780.62 Million | NT$269.65 Million | ▼ -34.4% |
| 2023 | 0.53x | NT$511.93 Million | NT$269.77 Million | ▲ +156.9% |
| 2022 | 0.21x | NT$630.25 Million | NT$129.29 Million | ▼ -2.1% |
| 2021 | 0.21x | NT$444.29 Million | NT$93.06 Million | ▼ -65.5% |
| 2020 | 0.61x | NT$254.40 Million | NT$154.41 Million | ▼ -96.9% |
| 2018 | 19.66x | NT$16.00 Million | NT$314.43 Million | ▲ +996.6% |
| 2016 | 1.79x | NT$236.48 Million | NT$423.92 Million | ▼ -88.5% |
| 2015 | 15.65x | NT$23.60 Million | NT$369.26 Million | — |